Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor–Resistant Melanoma

Authors

Keywords

Journal

Volume -, Issue -, Pages -

Publisher

American Association for Cancer Research (AACR)

Online

2021-08-11

DOI

10.1158/1535-7163.mct-20-1126

Discuss science. Find collaborators. Network.

Join a conversation

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now